A new scale for tumor DNA mutations which will simplify and standardize choices for targeted cancer treatment has been agreed by leading cancer specialists in Europe and North America. The scale, called ESCAT (ESMO Scale for Clinical Actionability of molecular Targets), aims to optimize patient care by making it easier to identify patients with cancer who are likely to respond to precision medicines, and help make treatment more cost effective.